In December 2024, CapSys Group launched a survey to executives in Biopharma to explore the importance of critical internal and external industry challenges and how prepared organizations feel they are to address them.
This report synthesizes insights from the “2025 Growth Challenges in Biopharma” survey, capturing feedback from 70 respondents across marketing, medical, market access and other functions. In addition, it highlights actions that biopharma teams are taking as well as our thoughts on the “Transformative Ideas” that biopharma leaders should consider for their most significant challenges going forward.
In future reports, we will examine on a topic-by-topic basis the deeper implications of these findings and our recommendations. Stay tuned for further insights into the most impactful perspectives for you.
Survey Findings – Key Highlights
- Internal challenges dominate the landscape, with respondents indicating a pronounced gap between importance and level of preparedness.
- External pressures, such as pricing scrutiny and the growing complexity of the stakeholder landscape, remain critical but are relatively better managed.
- Transformative opportunities lie in digital integration, cross-functional collaboration, talent development and managing change better.
